Drug profile

The FDA adverse-event record for Parasite Treatment

34 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Parasite Treatment. See the species affected, top reactions, and outcomes below.

34
adverse-event reports
11.8%
death-coded share
Dog
most-reported species
7
Lack of efficacy (endoparasite) - heartworm - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
34
Total Reports
4
Deaths Reported
11.8%
Death Rate

Active Ingredients

Parasite Treatment

Administration Routes

UnknownTopicalOral

Species Affected

Dog 26
Cat 4
Cattle 4

Most Affected Breeds

Retriever - Labrador 7
Pit Bull 5
Domestic Shorthair 3
Holstein-Friesian also known as Holstein 3
Great Pyrenees 2
Dog (other) 1
Mixed (Cattle) 1
Pointing Dog - German Short-haired 1
Saint Bernard Dog 1
Bulldog 1

Most Reported Reactions

Lack of efficacy (endoparasite) - heartworm 7
Behavioural disorder NOS 5
Other abnormal test result NOS 5
Vomiting 4
Lethargy (see also Central nervous system depression in 'Neurological') 4
Diarrhoea 4
Emesis 3
Weight loss 3
Cough 3
Death 3
Seizure NOS 2
Not eating 2

Outcome Breakdown

Outcome Unknown
21 (58.3%)
Recovered/Normal
7 (19.4%)
Ongoing
3 (8.3%)
Died
3 (8.3%)
Recovered with Sequela
1 (2.8%)
Euthanized
1 (2.8%)

Parasite Treatment Adverse Event Insights

34 reports name Parasite Treatment; 4 recorded a death outcome (11.8% of reported events, not a population-level mortality rate). Active ingredient: Parasite Treatment. Administration routes: Unknown, Topical, Oral.

By species: Dog (26 reports), Cat (4 reports), Cattle (4 reports). By breed: Retriever - Labrador (7), Pit Bull (5), Domestic Shorthair (3).

Leading clinical signs: Lack of efficacy (endoparasite) - heartworm (7), Behavioural disorder NOS (5), Other abnormal test result NOS (5), Vomiting (4). Outcome, 36 coded reports: Outcome Unknown leads at 58.3%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.